Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab induction study in moderately to severely active ulcerative colitis
NL-OMON54524Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risankizumab in autoimmune colitis (3 arms), sponsored by AbbVie Inc. Primary endpoint: Clinical remission at Week 12. Started Feb 2019; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON54524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54524.